Mr. Ramelli has served as a director since August 2012. Prior to his appointment as
chief executive officer, Mr. Ramelli worked as a consultant for several
investment funds providing in-depth due diligence and investment
recommendations on biotech companies. He has over 20 years of experience in the
investment industry, having worked as both an institutional equity trader and
as an equity analyst at Eos Funds, Robert W. Duggan & Associates and Seneca
Capital Management. Mr. Ramelli graduated with honors from U.C. Santa Barbara,
with a BA in Business Economics.
Dr. Templin joined Marina Biotech in December 2004. While at Marina Biotech (and its predecessors) he has served in a variety of management positions leading teams in the areas of discovery research and preclinical development. Before joining Marina Biotech he held research and development positions at Isis Pharmaceuticals, Amgen, and Zymogenetics. Dr. Templin's pharmaceutical development experience includes regulatory toxicology from bench research through IND and NDA filings for small- and large-molecule platforms (oligonucleotides, peptides, proteins, and antibodies). Dr. Templin received a Ph.D. in Pharmacology/Toxicology from Washington State University and completed a Postdoctoral Fellowship at the Chemical Industry Institute of Toxicology (RTP, NC Dr. Templin has held certification as a Diplomate of the American Board of Toxicology since 1998.